The presence of high affinity receptors for bombesin (BN)-like peptides on a wide variety of tumours prompted us to employ some of our powerful BN/gastrin releasing peptide (GRP) antagonists as carrier molecules for targeting cytotoxic agents to tumour cells (Nagy et al, 1997). The gene discussed is GRP; the disease is neoplasm.